Methods for cardioprotection and cardioregeneration with dimers of egf family ligands
US-2015343023-A1 · Dec 3, 2015 · US
Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
US9029328B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9029328-B2 |
| Application number | US-201113636578-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 24, 2011 |
| Priority date | Mar 24, 2010 |
| Publication date | May 12, 2015 |
| Grant date | May 12, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for reducing anthracycline-associated cardiotoxicity comprising administering to a subject in need of anthracycline therapy and reduced anthracycline-associated cardiotoxicity a neuregulin dimer, or a ligand dimer, in an amount effective to reduce anthracycline-associated cardiotoxicity, wherein each of the ligands of the ligand dimer comprises an epidermal growth factor (EGF), a neuregulin, or a spitz. 2. The method of claim…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K38/1808Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9029328B2 cover?
- The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, su…
- Who is the assignee on this patent?
- Jay Steven M, Griffith Linda G, Lee Richard T, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1808. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).